NEW YORK, Jan. 10, 2017 /PRNewswire/ -- BeyondSpring Inc., a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that Dr. Ramon Mohanlal, Chief Medical Officer, will present at Biotech Showcase 2017 during the annual JPMorgan Healthcare Conference in San Francisco. The presentation will take place on Tuesday, January 10, at 2:45 p.m. PT in Room One at the Hilton San Francisco Union Square (ballroom level).
Dr. Mohanlal's comments will be a corporate presentation of BeyondSpring Inc. BeyondSpring's innovative lead asset, Plinabulin, is a novel small molecule with immune-enhancing effects and anti-cancer activity that is given by IV infusion (one hour after chemotherapy), which has the potential to be a safe, cost-effective and convenient alternative to G-CSF, the current standard of care for chemotherapy-induced Neutropenia, with much less bone pain and a more favorable safety profile. Plinabulin is also being developed as an anti-cancer agent that targets and alters the tumor microenvironment. Plinabulin is expected to enter the market in 2019.
Management will be available for one-on-one meetings from January 10 through 12 at the Handlery Union Square Hotel, located at 351 Geary St., San Francisco. Please contact Matt Beck, The Trout Group, at 917.415.1750, mbeck@troutgroup.com to request a meeting.
About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring has advanced its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer. The Company is also planning a Phase 2/3 clinical trial for Plinabulin in the prevention of chemotherapy-induced Neutropenia. BeyondSpring's experienced management team brought a combined 30+ drugs to market.
About Plinabulin
Plinabulin is an innovative small molecule agent that has multiple mechanisms of action, with an immune enhancing mechanism and tumor vasculature targeting and activating JNK pathway to induce cancer cell apoptosis.
Company Contact:
Richard Brand
BeyondSpring Chief Financial Officer
201.577.8221, rbrand@beyondspringpharma.com
SOURCE BeyondSpring Inc.